The FDA decision on DBV Technologies S.A.’s (DBVT) peanut allergy treatment Viaskin Peanut, for children ages 4-11, is expected on August 5, 2020.The Viaskin Peanut is a skin patch that aims to desensitize children to allergens by delivering antigens in small quantities into the outer layers of the skin.This is DBV Tech’s second attempt at securing FDA approval. In 2018, the company had voluntarily withdrawn its Biologics License Application for Viaskin Peanut as the application lacked “sufficient detail regarding data on manufacturing procedures and quality controls.After making the needed changes, the company resubmitted the Biologics License Application last August. An FDA panel was slated to review Viaskin Peanut in May of this year, but was cancelled because in February, additional data regarding the product’s efficacy and impact of patch-site adhesion were sought by the regulatory agency.The first and only approved drug in the U.S. for peanut allergy in children is Aimmune’s Palforzia. This drug secured approval in February of this year. DBVT closed Friday’s (Jul.24, 2020) trading at $4.15, down 3.71%.